All patients received anti-HER2 therapy with taxane-based NACT; however, Pertuzumab was approved in Türkiye in October 2019 for neoadjuvant treatment of HER2-positive breast cancer, and Trastuzumab emtansine (T-DM1) was approved in Türkiye in November 2021, while adjuvant pertuzumab is not yet approved. Here, ERBB2 is linked to breast cancer.